Based on these findings, we have proposed that autoimmune diseases are "stem cell disorders".
To elucidate the difierences between normal and abnormal HSCs, we have very recently established a new method for purifying pluripotent HSCs (P-HSCs). Using P-HSCs purified by our method, we have compared normal and abnormal P-HSCs, and found that qualitative differences exist between them both in vivo and in vitro; although normal P-HSCs do not readily proliferate in major histocompatibility complex (MHC)-incompatible microenvironments, abnormal P-HSCs show a marked proliferative response even in the allogeneic environments.
Abnormal P-HSCs are thus more "resilient" than normal P-HSCs. I pients survived in good health for more than 3 months after BMT [14] . In BXSB and B/W F1 mice, BMT had completely curative effects. Glomerular damage was ameliorated , and the levels of autoantibodies (anti-DNA and anti-Sm antibodies [Abs] ) and circulating immune complexes (CICs), particularly gp-70 anti-gp-70 CICs, were reduced. The repair of glomerular damage was assessed by performing renal biopsies before and after BMT, as shown in Fig.  1 . In addition, immunological functions were normalized; T cell functions including IL-2 production were restored, and hyperfunctions of macrophages and B cells decreased.
Assays for both mixed-lymphocyte reaction (MLR) and the generation of cytotoxic T lymphocytes (CTL) revealed that newly developed T cells from BMTtreated mice were tolerant of both bone marrow donortype and host-type MHC determinants, but responded vigorously to third-party cells. In vitro primary antisheep red blood cell (SRBC) plaque-forming cell (PFC) assay also showed that some degree of co-operation was achieved among antigen-presenting cells (APC), helper T cells, and B cells.
III.
Prevention and Treatment of Organ-Specific Autoimmune Disease by BMT Plus Organ Allografts
We next examined whether organ-specific autoimmune diseases could be treated by BMT using an animal model for IDDM, the NOD mouse.
First, we attempted to prevent insulitis and overt diabetes by BMT. NOD mice (>4 months) were lethally irradiated and then reconstituted with T cell-depleted BALB/c bone marrow cells. The mice were killed more than 3 months after BMT. No lymphocyte infiltration was observed in the islets of the BMT-treated NOD mice. Immunohistochemical studies revealed the presence of intact beta cells as well as alpha and delta cells. BMTtreated NOD mice showed a normal pattern in glucose tolerance tests (GTTs). Diabetic nephropathy was also corrected by BMT. Thus, BMT can prevent insulitis and overt diabetes [15] . However, we could not treat overt diabetes in NOD mice by BMT, because mice with overt diabetes have no beta cells.
We next performed a combined transplantation of fetal or newborn pancreas plus allogeneic bone marrow, since we know that organ allografts are accepted if the organ is transplanted from the same donor as the bone marrow at the same time [31] . NOD mice that had already developed overt diabetes were lethally irradiated and then reconstituted with allogeneic BALB/c bone marrow cells. The pancreatic tissues from fetal or newborn BALB/c mice were then engrafted under the renal capsules of NOD diabetic mice. Three months after the transplantation, the mice exhibited a normal GTT pattern, and insulin levels in the sera were also normalized. Fig. 3 ) is due to the presence of anti-cardiolipin Abs, and that the mouse is an animal model for anti-phospholipid Ab syndrome [2] . The transplantation of bone marrow cells from normal mice to W/BF1 mice was found to exert preventative and curative effects on lupus nephritis, thrombocytopenia and anti-phospholipid Ab syndrome; the platelet counts were normalized, and circulating anti-platelet Ab levels as 7) . Fig. 7 . Necessity of stromal cells for P-HSCs to proliferate. When P-HSCs were cocultured with stromal cells, the P-HSCs proliferated without the addition of cytokines, whereas they did not without stromal cells. The morphology of P-HSCs was examined using an electron microscope. As shown in Fig. 8 , the cells had a large nucleus with narrow cytoplasm. Their chromatin pattern was dispersed, but small aggregates appeared at nuclear margins. There were few cytoplasmic organellas but abundant free ribosomes. It should be noted that P-HSCs possess microvilli; they show active movement like neutrophils, as observed on video tape.
IX. Qualitative Differences between Normal and
Abnormal P-HSCs
The next question was whether there are any qualitative differences between normal and abnormal P-HSCs.
To answer this question, we first carried out BMT between normal and autoimmune-prone mice using partially purified P-HSCs. The transplantation of bones plus abnormal P-HSCs obtained from autoimmune-prone mice induced autoimmune diseases in normal mice, as did transplantation of T cell-depleted bone marrow cells (TCO-BMCs) (Fig. 9) . However, the transplantation of bones plus normal P-HSCs could not reconstruct hemopoiesis in autoimmune-prone mice due to graft rejection (Fig. 10) [21] , although the transplantation of T celldepleted bone marrow cells from normal mice can be used to prevent and treat autoimmune diseases in autoimmune- prone mice [14-16], as described above. This finding suggests that abnormal P-HSCs are more resilient than normal P-HSCs; the former can proliferate in MHCmismatched microenvironments, while the latter cannot. This was also confirmed in in vitro experiments. As shown in Fig. 11 Recently, Marmont has reviewed these data in humans [27] .
XI.
Hypothetical Etiopathogenesis of Systemic and Organ-Specific Autoimmune Diseases
Based on the above observations (both in mice and humans), we have proposed a new concept of "stem cell disorders" including autoimmune diseases: i) stem cell aplasia (aplastic anemia), ii) monoclonal abnormal stem cell proliferative syndrome (leukemia and preleukemia), and iii) polyclonal abnormal stem cell proliferative syndrome (autoimmune diseases).
Regarding the etiopathogenesis of autoimmune diseases, our current hypothesis is as follows. As shown in Fig. 12 , polygene abnormalities primarily exist at the gene level of P-HSCs.
Probably endogenous or exogenous retroviruses are involved in the development of P-HSC abnormalities.
Autoreactive immunocompetent cells including T cells differentiate from the abnormal P-HSCs. In systemic autoimmune diseases, autoreactive T cells attack various organs as in chronic graft-versushost reaction (GVHR), resulting in systemic tissue injury (Fig. 12A) . In contrast, suppressor T cells play a crucial role in the development of organ-specific autoimmune diseases (Fig. 12B) , since we have some data suggesting that there is a correlation between decreased CD8+ suppressor T cell counts and the development of organ-specific autoimmune diseases (unpublished data) .
XII.
The Prospects for BMT
In humans, BMT across MHC-barriers has had a low success rate as a consequence of i) GVHR due to contamination with T cells from the peripheral blood and ii) graft rejection. We have provided evidence that, in mice, no such problems are associated with BMT. GVHR can be prevented if T cell-depleted bone marrow cells are used . Graft rejection can be prevented by bone grafts and the transplantation of natural suppressor cells (NSCs) [37, 38] . It is certain that similar conditions to permit successful BMT in humans will be realized in the near future. When such conditions have been achieved, we can expect BMT to become a valuable strategy for the treatment of patients with autoimmune diseases. Furthermore, we would like to suggest that organ allografts of heart, kidney, pancreas, etc., may be accomplished without using long-term immunosuppressants if the organ is obtained from the same donor as the bone marrow and both are transplanted at the same time.
In humans, it is well known that the success rate of BMT in patients more than 45 years old is low. Recently, we have found that the low success rate is due to the aging of the thymus, and that BMT plus embryonal thymus grafts can be used to not only treat late-onset autoimmune diseases in MRL/+ mice [13] but also prevent age-related amyloidosis in SAMP 1 mice (manuscript in preparation). We believe that this is due to the atrophy of the thymus, and that transplantation of the embryonal thymus in conjunction with BMT should become a valuable strategy for older patients with various diseases.
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